## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.26)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. State Board of Administration of Florida Retirement System Cuts Stake in Medtronic PLC $MDT**
- Source: MarketBeat | 20251129T121829 | Neutral | Relevance: 99%
- The State Board of Administration of Florida Retirement System reduced its stake in Medtronic PLC by 1.3% in Q2, selling 15,917 shares but still owning 1,219,635 shares valued at $106.3 million. While institutional ownership remains high at 82.06% with other major firms increasing their positions, an EVP also sold a significant portion of his holdings. Medtronic reported an earnings beat and revenue growth, issuing positive FY2026 EPS guidance, and holds a consensus "Moderate Buy" rating.

**2. Barclays Adjusts Medtronic (MDT) Forecast After Encouraging Earnings Report**
- Source: Yahoo Finance UK | 20251130T191100 | Bullish | Relevance: 99%
- Barclays raised its price target for Medtronic plc (MDT) to $111 from $109, maintaining an Overweight rating, after the company reported strong second-quarter fiscal 2026 results. Medtronic's sales reached $9 billion, a 6.6% increase year-over-year, and adjusted EPS grew 8% to $1.36, both exceeding analyst projections. The cardiovascular segment was a significant contributor to this growth, with revenue up 10.8%.

**3. Barclays Adjusts Medtronic (MDT) Forecast After Encouraging Earnings Report**
- Source: Finviz | 20251130T141100 | Bullish | Relevance: 99%
- Barclays has increased its price target for Medtronic plc (MDT) to $111 from $109, maintaining an Overweight rating, after the company reported strong Q2 fiscal 2026 earnings. Medtronic's sales grew 6.6% year-over-year to $9 billion with adjusted EPS up 8% to $1.36, both exceeding analyst expectations. The cardiovascular segment was a significant driver of growth, experiencing its fastest rate in over a decade.

**4. Medtronic (MDT) Price Target Raised as PFA Technology Drives Q2 Revenue Gains**
- Source: Finviz | 20251129T130900 | Bullish | Relevance: 99%
- Truist Securities increased its price target for Medtronic (MDT) to $110 from $103, following revenue growth driven by the companyâ€™s Pulsed Field Ablation (PFA) technology in its fiscal second quarter. While CAS division sales saw a significant organic rise, an operating margin miss was noted due to increased reinvestment ahead of new product releases. Medtronic, a leader in medical technology, is strategically investing, which is limiting short-term profit acceleration despite strong revenue.

**5. Barclays Adjusts Medtronic (MDT) Forecast After Encouraging Earnings Report**
- Source: Insider Monkey | 20251130T141100 | Bullish | Relevance: 98%
- Barclays raised its price target for Medtronic (MDT) to $111 from $109 while maintaining an Overweight rating following a strong fiscal Q2 2026 earnings report. Medtronic reported sales of $9 billion, a 6.6% increase, and adjusted EPS of $1.36, both exceeding analyst projections. The cardiovascular segment was a key contributor, growing 10.8% year over year.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Forward P/E 16.9x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $129.2B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.9 |
| Current P/E | 18.3 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.2% to -0.9% (-5.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.88), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.86% (CS: 47) | Neutral |
| RSI_14 | 67.2 | Neutral |
| MACD Histogram | 0.88 | Bullish |
| vs SMA20 | 1.060x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.142x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $103.34
- **Stop Loss:** $99.26 (3.9% risk)
- **Target:** $107.42 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 183
- **Position Value:** $18,911.22
- **Portfolio %:** 18.91%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*